Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentis in Retinoblastoma
NCT01899066Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2013
- Primary completion
- Dec 2015
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ranibizumab in retinoblastoma (Rb), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
ranibizumab
03
Conditions
retinoblastoma (Rb)
Beyond the preview
Go deeper on NCT01899066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01899066.